KOREA PHARMA Co., Ltd. (KOSDAQ:032300)

KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 137.86 billion. The enterprise value is 142.67 billion.

Market Cap	137.86B
Enterprise Value	142.67B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 29, 2025

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 15.73% in one year.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	+15.73%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	63.38%
Owned by Institutions (%)	0.01%
Float	3.99M

Valuation Ratios

The trailing PE ratio is 791.60.

PE Ratio	791.60
Forward PE	n/a
PS Ratio	1.53
PB Ratio	1.94
P/TBV Ratio	2.04
P/FCF Ratio	n/a
P/OCF Ratio	26.17
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.83, with an EV/FCF ratio of -8.65.

EV / Earnings	819.22
EV / Sales	1.58
EV / EBITDA	17.83
EV / EBIT	29.11
EV / FCF	-8.65

Financial Position

The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.54.

Current Ratio	1.70
Quick Ratio	1.17
Debt / Equity	0.54
Debt / EBITDA	5.93
Debt / FCF	-2.32
Interest Coverage	1.00

Financial Efficiency

Return on equity (ROE) is 0.24% and return on invested capital (ROIC) is 4.34%.

Return on Equity (ROE)	0.24%
Return on Assets (ROA)	1.73%
Return on Invested Capital (ROIC)	4.34%
Return on Capital Employed (ROCE)	3.83%
Weighted Average Cost of Capital (WACC)	10.27%
Revenue Per Employee	672.48M
Profits Per Employee	1.30M
Employee Count	134
Asset Turnover	0.75
Inventory Turnover	2.59

Taxes

Income Tax	-171.91M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.97% in the last 52 weeks. The beta is 1.26, so KOREA PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.26
52-Week Price Change	-22.97%
50-Day Moving Average	13,267.80
200-Day Moving Average	14,117.75
Relative Strength Index (RSI)	45.58
Average Volume (20 Days)	18,467

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 90.11 billion and earned 174.16 million in profits. Earnings per share was 15.95.

Revenue	90.11B
Gross Profit	34.98B
Operating Income	3.34B
Pretax Income	2.24M
Net Income	174.16M
EBITDA	6.44B
EBIT	3.34B
Earnings Per Share (EPS)	15.95

Balance Sheet

The company has 33.43 billion in cash and 38.24 billion in debt, with a net cash position of -4.81 billion or -441.02 per share.

Cash & Cash Equivalents	33.43B
Total Debt	38.24B
Net Cash	-4.81B
Net Cash Per Share	-441.02
Equity (Book Value)	71.01B
Book Value Per Share	6,511.12
Working Capital	29.48B

Cash Flow

In the last 12 months, operating cash flow was 5.27 billion and capital expenditures -21.76 billion, giving a free cash flow of -16.49 billion.

Operating Cash Flow	5.27B
Capital Expenditures	-21.76B
Free Cash Flow	-16.49B
FCF Per Share	-1,512.08

Margins

Gross margin is 38.82%, with operating and profit margins of 3.71% and 0.19%.

Gross Margin	38.82%
Operating Margin	3.71%
Pretax Margin	0.00%
Profit Margin	0.19%
EBITDA Margin	7.15%
EBIT Margin	3.71%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.41%.

Dividend Per Share	50.00
Dividend Yield	0.41%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	313.13%
Buyback Yield	-15.73%
Shareholder Yield	-15.32%
Earnings Yield	0.13%
FCF Yield	-11.96%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 3.03 and a Piotroski F-Score of 6.

Altman Z-Score	3.03
Piotroski F-Score	6